Please use this identifier to cite or link to this item:
Title: Dimethyl fumarate reduces inflammation in chronic active multiple sclerosis lesions
Authors: Zinger, Nicole
Ponath, Gerald
Sweeney, Elizabeth
Nguyen, Thanh D.
Lo, Chih Hung
Diaz, Ivan
Dimov, Alexey
Teng, Leilei
Zexter, Lily
Comunale, Joseph
Wang, Yi
Pitt, David
Gauthier, Susan A.
Keywords: Science::Medicine
Issue Date: 2022
Source: Zinger, N., Ponath, G., Sweeney, E., Nguyen, T. D., Lo, C. H., Diaz, I., Dimov, A., Teng, L., Zexter, L., Comunale, J., Wang, Y., Pitt, D. & Gauthier, S. A. (2022). Dimethyl fumarate reduces inflammation in chronic active multiple sclerosis lesions. Neurology® Neuroimmunology & Neuroinflammation, 9(2), e1138-.
Journal: Neurology® neuroimmunology & neuroinflammation
Abstract: BACKGROUND AND OBJECTIVES: To determine the effects of dimethyl fumarate (DMF) and glatiramer acetate on iron content in chronic active lesions in patients with multiple sclerosis (MS) and in human microglia in vitro. METHODS: This was a retrospective observational study of 34 patients with relapsing-remitting MS and clinically isolated syndrome treated with DMF or glatiramer acetate. Patients had lesions with hyperintense rims on quantitative susceptibility mapping, were treated with DMF or glatiramer acetate (GA), and had a minimum of 2 on-treatment scans. Changes in susceptibility in rim lesions were compared among treatment groups in a linear mixed effects model. In a separate in vitro study, induced pluripotent stem cell-derived human microglia were treated with DMF or GA, and treatment-induced changes in iron content and activation state of microglia were compared. RESULTS: Rim lesions in patients treated with DMF had on average a 2.77-unit reduction in susceptibility per year over rim lesions in patients treated with GA (bootstrapped 95% CI -5.87 to -0.01), holding all other variables constant. Moreover, DMF but not GA reduced inflammatory activation and concomitantly iron content in human microglia in vitro. DISCUSSION: Together, our data indicate that DMF-induced reduction of susceptibility in MS lesions is associated with a decreased activation state in microglial cells. We have demonstrated that a specific disease modifying therapy, DMF, decreases glial activity in chronic active lesions. Susceptibility changes in rim lesions provide an in vivo biomarker for the effect of DMF on microglial activity. CLASSIFICATION OF EVIDENCE: This study provided Class III evidence that DMF is superior to GA in the presence of iron as a marker of inflammation as measured by MRI quantitative susceptibility mapping.
ISSN: 2332-7812
DOI: 10.1212/NXI.0000000000001138
Schools: Lee Kong Chian School of Medicine (LKCMedicine) 
Rights: © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
Fulltext Permission: open
Fulltext Availability: With Fulltext
Appears in Collections:LKCMedicine Journal Articles

Files in This Item:
File Description SizeFormat 
e1138.full.pdf508.61 kBAdobe PDFThumbnail

Citations 20

Updated on Jun 11, 2024

Web of ScienceTM
Citations 20

Updated on Oct 28, 2023

Page view(s)

Updated on Jun 18, 2024


Updated on Jun 18, 2024

Google ScholarTM




Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.